Melanoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 55
• BRAF 18
• PD-L1 22
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• CTNNB1 0
• RAS 2
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• HDAC 1
• IDH 1
• IL-17 1
• MET 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

EU-13 is a filter, not a ranking: it only narrows the list.

17 of 17+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Deciphera Pharmaceuticals, LLC· Updated 5 Mar 2026

  “Trial terminated due to a business decision, not based on any safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Study of IK-595 in RAS- or RAF-altered Advanced Tumors

  NCT06270082· Ikena Oncology· Updated 19 Sept 2025

  “Limited resources and strategic priorities”Registry text, quoted unchanged. Source

• Suspended

  JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

  NCT04418167· JS InnoPharm, LLC· Updated 3 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

  NCT07121829· Day One Biopharmaceuticals, Inc.· Updated 14 Aug 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

  NCT07891286· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 21
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 46
• Metabolomics 20
• Mass Spectrometry 9
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 120
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 56
• Machine Learning 47
• Deep Learning 44
• Cohort Studies 77
• Genome-Wide Association Study 22

See which targets of this disease your abstract mentions, and go to the people working on them.